Marincola brings decades of Experience in Leadership at the National Institutes of Health, held distinguished Executive Leadership Positions with BioPharmaceutical Companies, and was the founding Editor of Journal of Translational Medicine
MADISON, Wis., June 3, 2026 –Elephas Biosciences Corporation today announced the appointment of Dr. Francesco Marincola to the company's Scientific Advisory Board (SAB). Elephas uses their elive™ platform to preserve the native tumor microenvironment to deliver real-time functional insights from live human tumor tissue.
Dr. Marincola joins Elephas at a pivotal stage as the company advances global commercialization efforts, expands strategic clinical collaborations, and accelerates discovery through elive.
Widely recognized as a pioneer in translational immunology and immunotherapy research, Dr. Marincola brings more than three decades of leadership experience spanning academia, government research institutions, and global biopharmaceutical companies. He currently serves as the Chief Scientific Officer & Global Head of Research at Translational and Advanced Medicine (TAM). Previously, he held scientific leadership roles at Sonata Therapeutics, Kite Pharma and Refuge Biotechnologies. Most notably prior to Refuge, Dr. Marincola was a Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre.
Beyond his distinguished industry leadership, Dr. Marincola served as the President of the Society for Immunotherapy of Cancer (SITC) and is the founding Editor-in-Chief of the Journal of Translational Medicine. He has authored more than 700 peer-reviewed publications focused on tumor immunology, biomarkers and translational cancer research.
“Understanding how tumors physically and biologically respond to treatment has long been one of the most important challenges in advancing immunotherapy,” said Dr. Marincola. “Elephas’ approach to measuring live tumor responses in real time has the potential to significantly improve how researchers and clinicians understand therapeutic effectiveness and guide treatment decisions for patients with cancer. I’m excited to support the company during this important stage of growth.”
Dr. Marincola joins the Scientific Advisory Board alongside:
“Dr. Marincola has made an invaluable impact through his discoveries in tumor immunology and biomarker development” said Maneesh Arora, Elephas Founder and CEO. “His expertise aligns precisely with where Elephas is headed, and we are honored to have him join our Scientific Advisory Board.”
About Elephas Biosciences
Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite a significant increase in the number of available immunotherapies, only 1 in 5 patients receiving immunotherapy obtain a response and many who may respond are not eligible for therapy due to lack of accurate predictive biomarkers. With the mission to tackle this massive dilemma, Elephas has developed an ex-vivo platform to assess how live biopsies respond to immunotherapies. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the elive platform enables a real-time characterization of immune response. To learn more, visit www.elephas.com and follow us on LinkedIn.
Media Contact
John Fitzpatrick
Investor Contact
Ji-Yon Yi